Seven factors predict a delayed diagnosis of cardiac amyloidosis

References

• Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103:1065–1072.
   PubMed Web of Science ®Google Scholar
• Maleszewski JJ, Murray DL, Dispenzieri A, et al. Relationship between monoclonal gammopathy and cardiac amyloid type. Cardiovasc Pathol. 2013;22:189–194.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34:520–508.
   Web of Science ®Google Scholar
• Luigetti M, Conte A, Del Grande A, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013;34:1057–1063.
   PubMed Web of Science ®Google Scholar
• Connors LH, Yamashita T, Yazaki M, et al. A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid. 2004;11:61–66.
   PubMed Web of Science ®Google Scholar
• Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium. Adv Ther. 2015;32:920–908.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Alaarmi S, Leipsic J, et al. Comparison of AL and TTR cardiac amyloidosis: a single center Canadian experience. Can J Cardiol. 2013;29:S114–S115.
   Web of Science ®Google Scholar
• Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med. 2015;372:21–29.
   PubMed Web of Science ®Google Scholar
• Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78:74–82.
   PubMed Web of Science ®Google Scholar
• Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425–1429.
   PubMed Web of Science ®Google Scholar
• Atroshi I, Gummesson C, Johnsson R, et al. Prevalence of carpal tunnel syndrome in a general population. JAMA. 1999;282:153–158.
   PubMed Web of Science ®Google Scholar
• Ikram A, Sperry B, Reyes B, et al. Carpal tunnel syndrome and amyloid cardiomyopathy. J Cardiol Fail. 2017;23:S11–S12.
   Web of Science ®Google Scholar
• Papoutsidakis N, Miller EJ, Rodonski A, et al. Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis. J Cardiol Fail. 2018;24:131–133.
   PubMed Web of Science ®Google Scholar
• Qian G, Wu C, Zhang Y, et al. Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis. J Geriatr Cardiol. 2014;11:136–140.
   PubMedGoogle Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. JCO. 2012;30:989–995.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787–1789.
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222–228.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Muchtar E, Gertz MA. Newer therapies for amyloid cardiomyopathy. Curr Heart Fail Rep. 2016;13:237–246.
   PubMedGoogle Scholar
• Maurer MS, Grogan DR, Judge DP, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519–526.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585–2594.
   PubMed Web of Science ®Google Scholar
• Antoni G, Lubberink M, Estrada S, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54:213–220.
   PubMed Web of Science ®Google Scholar
• Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–1579.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–2412.
   PubMed Web of Science ®Google Scholar